SÃO PAULO, August 15, 2026, 15:05 BRT – Shares of Ambev retreated by 6.7% following a slide in the Brazilian real, adding pressure to the ongoing stock selloff.
- Ambev ADRs dropped 6.7% over the past week, ending Friday at $2.80.
- Brazil’s stock market declined by 4.7%, and the real fell roughly 2.5%.
- Organic EBITDA in the second quarter increased by 8.9%, surpassing the rate of revenue growth.
Ambev S.A. NYSE:ABEV closed a turbulent week at $2.80. The ADR dropped 6.7% across five sessions, even as second-quarter margins remained strong. On Friday, trading volume stood at 38.4 million shares, roughly 39% higher than its three-month average.
The decline was not solely due to beer-related factors. Shares of Ambev in São Paulo BVMF:ABEV3 dropped 4.7%. At the same time, the Brazilian real depreciated by around 2.5% against the dollar. As a result, forex movement accounts for nearly two percentage points of the drop in ADRs.
| Instrument | Aug. 7 close | Aug. 14 close | Weekly change |
|---|---|---|---|
| Ambev ADR (USD) | $3.00 | $2.80 | fell 6.7% |
| Ambev local share (BRL) | R$15.48 | R$14.75 | lost 4.7% |
| Brazilian real per U.S. dollar | R$5.1218 | R$5.2132 | real down 1.8% |
Brewer shares declined across the board. Anheuser-Busch InBev (EBR:ABI) fell 6.5% in Brussels. Heineken N.V. AMS:HEIA shed 7.7%, and Fomento Económico Mexicano NYSE:FMX retreated 7.4%. The moves suggest overall sector risk reduction, not just a single Ambev event.
| Company | Listing | Aug. 7 close | Aug. 14 close | Weekly change |
|---|---|---|---|---|
| Ambev | NYSE:ABEV | $3.00 | $2.80 | -6.7% |
| AB InBev | EBR:ABI | €73.42 | €68.62 | -6.5% |
| Heineken | AMS:HEIA | €79.68 | €73.52 | -7.7% |
| FEMSA | NYSE:FMX | $127.73 | $118.27 | -7.4% |
The most recent operating report presents a contrasting view. Organic revenue for the second quarter climbed 6.1%. Organic normalized EBITDA advanced 8.9%, with the margin expanding by 80 basis points. Normalized profit rose 23.3% to R$3.49 billion.
| Q2 metric | 2025 | 2026 | Change |
|---|---|---|---|
| Volume | 39.57 million hl | 39.73 million hl | +1.4% organic |
| Net revenue | R$20.09 billion | R$20.15 billion | +6.1% organic |
| Normalized EBITDA | R$6.15 billion | R$6.38 billion | +8.9% organic |
| Normalized EBITDA margin | 30.6% | 31.6% | +80 bps organic |
| Normalized profit | R$2.83 billion | R$3.49 billion | +23.3% reported |
Brazilian beer was the main growth driver in the quarter, as volume increased by 5.0% and revenue advanced 8.9%. Premium beer volume saw growth in the mid-twenties. Non-alcoholic beverage volume in Brazil declined by 4.4%.
| Business unit | Volume growth | Organic revenue growth |
|---|---|---|
| Brazil beer | up 5.0% | rise of 8.9% |
| Brazil non-alcoholic beverages | down 4.4% | increase of 1.4% |
| Central America and Caribbean | gain of 5.4% | up 7.1% |
| Latin America South | drop of 2.9% | growth of 4.4% |
| Canada | decline of 1.8% | rise of 2.1% |
Chief Executive Carlos Lisboa described the quarter as “another quarter of beer volume growth, with solid top and bottom-line performance.” Data backs up this statement. Revenue per hectoliter climbed by 4.6%, and cash cost per hectoliter went up 2.2% when marketplace sales are excluded.
Valuation is further supported by cash returns. As of July 30, Ambev finished around 95% of its repurchase program for 208 million shares. The company has distributed about R$5.9 billion to shareholders this year prior to withholding tax. An additional R$1.9 billion in interest-on-capital is scheduled for October 6.
Analysts are taking a cautious stance. According to Ambev’s analyst coverage list, there are four Buy ratings, 11 Neutral, and three Sell recommendations. This division points to solid execution despite soft category demand and ongoing currency risks.
| Recommendation | Analysts | Selected firms |
|---|---|---|
| Buy | 4 | BTG Pactual, Evercore ISI, HSBC, Scotiabank |
| Hold | 11 | Barclays, JPMorgan, UBS |
| Sell | 3 | Goldman Sachs, Morgan Stanley, XP |
An ADR poll of 11 analysts yields a Hold consensus rating with an average price target of $3.36. Price estimates range between $2.55 and $4.00. Based on Friday’s closing price, this implies a 9% downside to a 43% upside. These forecasts were last revised on May 14, prior to the latest earnings report.
No Ambev report is on the calendar for the upcoming week. Third-quarter results will come on October 29. Market participants will focus on the real and the broader brewing sector. The ADR’s currency spread may shift swiftly.
Risks: A decline in the real weakens dollar-denominated ADR values. Reduced consumer demand may weigh on volume, and fluctuations in commodity and currency costs could erode margins. Analyst price targets remain highly uncertain.
The main test is straightforward. Should local shares hold steady while the ADR underperforms, currency remains the primary factor. If both continue to decline, investors are adjusting their expectations for Ambev’s operations.
Related articles: NYSE:ABEV
